$26.36−1.54 (−5.52%)
Market open · 15-min delayed · as of 10:45 AM ET
Nanobiotix · Overview
Industry: Drugs · see every company filed here →
Nanobiotix scores 40/100. Weak. Strongest on growth, value is the soft spot versus 400 Healthcare peers.
Tenet Score · vs sector
n=400Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value6
Quality53
Health13
Growth90
Factor grades
Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityCHealthFGrowthAMomentumA
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Price
Loading chart…
P/E
—
net income to common shareholders is not on file for this year
P/B
—
no P/B on file
P/S
35.3×
price to sales
ROE
—
negative equity denominator
Operating margin
−33.2%
before interest and tax
Net margin
−73.5%
fiscal 2025
Current ratio
1.09
fiscal 2025
Net debt / EBITDA
—
negative EBITDA denominator
EPS CAGR 2y
—
needs five years of positive earnings
Market cap
$1.3B
small cap
Div yield
—
no yield on file
52-wk range
14.78 – 57.14
low → high
Market cap: share price × the latest quarter's diluted weighted-average share count (vendor).
The whole report, at a glance · every card is a live peek, click any to open the section
Tenets
0 / 17
- ✕ Piotroski F-Score
- ✕ Quality Compounder
- ✕ Drawdown Context
- ✕ Reversal Evidence
- ✕ Not-a-Value-Trap Gate
- ~ Quality Floor
+11 more →
Financials
Revenue, margins and the five-year statements.Analyst Forecasts
Consensus estimates are on the Analyst tab.
Earnings
TBA
next reportBeat/miss history appears here after the first tracked report.Statistics
No ratios yet.Technical Analysis
Downtrend short-term signalvs 50-day−26.8%
vs 200-day−16.4%
RSI (14)28
News & Insights
Headlines are on the News tab.Dividends
No dividend. Cash stays in the business.Ownership
11% institutional
13F flows & insider trades land here.
About Nanobiotix
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of so…
Composite computed 2026-10-02 · peer basis: Healthcare (n=400) · every glimpse links to its full section with sources · not investment advice.
ETF exposure
Free account: the funds that hold NBTX, and at what weight. Everything else on this page stays open.Create a free account